A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease

Summary

This is a Phase II, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of IBI355 in participants with moderate-to-severe Sj?gren's disease (SjD).

Timeline

Start

2026-10-15

Primary completion

2027-11-01

Completion

2028-10-31

Drugs

Indications